CardieX Ltd (ASX:CDX) subsidiary ATCOR has been granted a new patent by the US Patent and Trademark Office (USPTO) for the intellectual property (IP) surrounding its patented SphygmoCor® technology.
US Patent No 11,006,842 'Non-Invasive Brachial Blood Pressure Measurement' protects the company’s IP in relation to the measurement of central blood pressure waveforms using a brachial blood pressure cuff.
Shares have been as much as 6.3% higher today to A$0.068 on the back of the announcement, which further builds on the company's 13 existing patents surrounding the measurement of cardiovascular health parameters using traditional brachial cuff devices as well as sensor-based wearable technologies.
Two-pronged strategy
In May 2020, ATCOR also lodged an additional new patent application for what is believed to be a world-first wearable sensor technology method and system using a PPG sensor - which the company is incorporating in upcoming product releases.
This is part of the company’s two-pronged diversification strategy, investing in med-tech products and consumer wearable devices.
ATCOR will continue the traditional business of cardiovascular solutions for the medical and clinical markets, and separately the company is set to reveal a new consumer-focused brand in the near term.
Consumer devices in development
CardieX is developing three new consumer devices, including the much-anticipated Pulse - a world-first dual blood pressure monitor incorporating CardieX’s patented central blood pressure technology and multiple new, patent-pending, heart-health parameters, based on ATCOR’s FDA-cleared SphygmoCor® technology.
The product launch of the ATCOR Pulse device is anticipated for late Q2/FY22.
The company is also developing a smartwatch with its patented technology in collaboration with Mobvoi, expected to launch early Q1/FY22, and the new Arty Band - a consumer wearable that provides advanced health diagnostics to consumers, including ‘cuffless’ blood pressure monitoring.